| Autor: |
de Arriba de la Fuente F; Hematology Department, Hospital Universitario Morales Meseguer, IMIB-Pascual Parrilla, Universidad de Murcia, 30008 Murcia, Spain., Gironella Mesa M; Hematology Department, Hospital Universitario Vall d'Hebrón, 08035 Barcelona, Spain., Hernández García MT; Hematology Department, Hospital Universitario de Canarias, 38320 La Laguna, Spain., Soler Campos JA; Hematology Department, Hosptial Universitario Parc Taulí, 08208 Barcelona, Spain., Herráez Rodríguez S; Hematology Department, Hospital Universitario Basurto, 48013 Bilbo, Spain., Moreno Belmonte MJ; Hematology Department, Hospital Universitario Virgen de la Arrixaca, 30120 Murcia, Spain., Regueiro López T; Spanish Multiple Myeloma Patient Community (CEMMP), 24560 León, Spain., González-Pardo M; Medical Department, Janssen-Cilag S.A., Johnson & Johnson Company, 28042 Madrid, Spain., Casanova Espinosa M; Department of Hematology/Clinical Oncology, Hospital Costa del Sol, 29603 Marbella, Spain., On Behalf Of The Carinae Study Investigators |
| Abstrakt: |
Real-world evidence on the impact of monoclonal antibodies as first-line treatment in Spain is limited. This observational, retrospective and prospective, multicenter, descriptive study included 117 transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM) patients divided into Group A, who received no daratumumab standard regimens, and the DVMP group (daratumumab, bortezomib, melphalan, and prednisone treatment). More than 90% of the patients in Group A received bortezomib, lenalidomide, or a combination of them. The median follow-up time for Group A was 38.2 months in comparison to 25.8 months for the DVMP group ( p < 0.0001). The rate of DVMP patients that experienced disease progression or death from any cause was 36.8%, compared to 67.3% of Group A patients at 36 months of follow-up. The DVMP group had a higher 36-month progression-free survival (PFS) rate (52.9% vs. 31.7%). During the retrospective period, 73.0% of patients reported adverse drug reactions, while in the prospective period, 40.5% experienced adverse events, with no clinical differences between groups. The study supports the use of daratumumab regimens in frontline therapy based on real-world data. The findings provide valuable insights into the clinical outcomes of daratumumab therapy, which can help physicians make informed decisions regarding the optimal treatment approach for this patient population. |
